10 completed, 2 active not recruiting, 2 terminated, 1 unknown. 15 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Completed 10, Active not recruiting 2, Terminated 2, Unknown 1 |
| Phase 2 | 7 | Completed 7 |
Follow Matrix-M: new trials by email Literature Review of Matrix-M trials Research Report on Matrix-M
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine) R21, RH5.1, R78C - Malaria,Falciparum | Phase 1 | Active not recruiting | University of Oxford | 56 | 2025-09-15 | 2026-10-21 |
| Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults R21, Pfs230D1-CRM197, Pfs230D1-EPA - Prevention of Malaria Transmission and Clinical Malaria | Phase 1 | Completed | Serum Institute of India Pvt. Ltd. | 240 | 2024-08-30 | 2026-02-10 |
| Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator - Epstein-Barr Virus Infection, Infectious Mononucleosis | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 25 | 2023-09-22 | 2026-04-22 |
| A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines RH5.1 and/or RH5.2-VLP with Matrix-M - Malaria, Malaria,Falciparum | Phase 1 / Phase 2 | Completed | University of Oxford | 41 | 2023-08-18 | 2026-07-20 |
| A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21 Matrix-M with RH5.2 VLP and/or R21 - Malaria, Plasmodium Falciparum | Phase 1 | Completed | University of Oxford | 107 | 2023-07-10 | 2026-05-12 |
| A Study to Compare Two Dosing Regimens for a New Malaria Vaccine Matrix M with RH5.1 - Malaria, Malaria,Falciparum | Phase 1 | Active not recruiting | University of Oxford | 24 | 2023-06-06 | 2024-10-04 |
| A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso. Rabies vaccine, RH5.1 10μg adjuvated with 50μg Matrix-M, RH5.2 5μg adjuvated with 50μg Matrix-M - Malaria,Falciparum | Phase 1 / Phase 2 | Completed | University of Oxford | 390 | 2023-04-03 | 2026-10-21 |
| Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine ICC Vaccine, qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant, SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant - SARS-CoV Infection, Covid19 | Phase 1 / Phase 2 | Completed | Novavax | 637 | 2021-09-08 | 2025-04-10 |
| Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania. Pfs25-IMX313 (10ug)/Matrix-M (50ug), Pfs25-IMX313 (50ug)/Matrix-M (50ug), Pfs25-IMX313 (50ug)/Matrix-M (50ug) & Pfs25-IMX313 (10ug)/Matrix-M (50ug) - Malaria,Falciparum | Phase 1 | Terminated | University of Oxford | 34 | 2021-05-25 | 2025-01-27 |
| Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1 PvDBPII/Matrix-M1 - Malaria, Vivax | Phase 1 / Phase 2 | Completed | University of Oxford | 24 | 2020-01-24 | 2024-11-25 |
| VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine Pfs25-IMX313/Matrix-M1 - Malaria,Falciparum | Phase 1 | Terminated | University of Oxford | 1 | 2019-09-27 | 2020-09-29 |
| Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso R21 adjuvanted with 25mcg Matrix-M, Rabies Vaccine, R21 adjuvanted with 50mcg Matrix-M - Malaria,Falciparum | Phase 1 / Phase 2 | Completed | University of Oxford | 450 | 2019-05-07 | 2025-07-11 |
| A Safety and Efficacy Study of R21 +/- ChAd63/MVA ME-TRAP R21 with Matrix-M1, ChAd63 ME-TRAP, MVA ME-TRAP - Malaria | Phase 1 / Phase 2 | Completed | University of Oxford | 63 | 2016-08-01 | 2018-06-13 |
| A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1 R21, Matrix-M1 - Malaria | Phase 1 | Completed | University of Oxford | 31 | 2015-10-15 | 2019-11-12 |
| Study of Parenterally Administrated Adjuvanted Seasonal Influenza Vaccine in Healthy Elderly Volunteers Matrix M, Seasonal influenza vaccine - Influenza | Phase 1 | Unknown | Isconova AB | 110 | 2011-05-01 | 2011-09-30 |
Malaria, Falciparum (8) · Malaria (4) · Infections (2) · Parasitic Diseases (2) · Vector Borne Diseases (2) · COVID-19 (1) · Coronavirus Infections (1) · Epstein-Barr Virus Infections (1) · Herpes Simplex (1) · Infectious Mononucleosis (1) · Influenza, Human (1) · Malaria, Vivax (1) · Protozoan Infections (1) · Severe Acute Respiratory Syndrome (1)
University of Oxford (11) · Isconova AB (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novavax (1) · Serum Institute of India Pvt. Ltd. (1)
United Kingdom (6) · Burkina Faso (3) · Australia (1) · Hungary (1) · Mali (1) · Tanzania (1) · The Gambia (1) · United States (1)
Angela Minassian (2) · Adrian V Hill, DPhil FRCP (1) · Angela M Minassian, Dr (1) · Angela Minassian, Dr (1) · Angela Minassian, PhD (1) · Jessica R Durkee-Shock, M.D. (1) · Umberto D'Alessandro (1)
PMID 30774635, PMID 33964223, PMID 35664997, PMID 36087586, PMID 39672183, PMID 39805301, PMID 39805302, PMID 40245769, PMID 41176969